NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jun 20 04:00PM ET
1.22
Dollar change
-0.01
Percentage change
-0.81
%
Index- P/E- EPS (ttm)-0.50 Insider Own25.79% Shs Outstand16.81M Perf Week-1.61%
Market Cap20.64M Forward P/E- EPS next Y-0.33 Insider Trans0.00% Shs Float12.56M Perf Month-6.87%
Enterprise Value19.43M PEG- EPS next Q-0.13 Inst Own5.72% Short Float1.88% Perf Quarter0.00%
Income-7.92M P/S- EPS this Y26.67% Inst Trans-13.74% Short Ratio0.19 Perf Half Y10.91%
Sales0.00M P/B15.85 EPS next Y15.58% ROA-304.03% Short Interest0.24M Perf YTD7.02%
Book/sh0.08 P/C17.06 EPS next 5Y- ROE-355.82% 52W Range0.51 - 5.01 Perf Year69.44%
Cash/sh0.07 P/FCF- EPS past 3/5Y-51.03% -224.25% ROIC-611.87% 52W High-75.65% Perf 3Y-
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- 52W Low139.22% Perf 5Y-
Dividend TTM- EV/Sales- EPS Y/Y TTM37.57% Oper. Margin- Volatility3.30% 3.28% Perf 10Y-
Dividend Ex-Date- Quick Ratio12.86 Sales Y/Y TTM- Profit Margin- RSI (14)46.37 Recom3.00
Dividend Gr. 3/5Y- - Current Ratio12.86 EPS Q/Q-22.94% SMA20-5.65% Beta1.99 Target Price17.75
Payout- Debt/Eq0.00 Sales Q/Q- SMA503.50% Rel Volume0.07 Prev Close1.23
Employees5 LT Debt/Eq0.00 EarningsMay 28 SMA2000.63% Avg Volume1.22M Price1.22
IPOAug 03, 2023 Option/ShortNo / Yes EPS/Sales Surpr.15.38% - Trades Volume84,335 Change-0.81%
Jun-18-25 08:30AM
May-28-25 08:30AM
May-11-25 03:33PM
May-09-25 11:11AM
May-08-25 08:00AM
07:16AM Loading…
07:16AM
May-06-25 08:00AM
07:16AM
Apr-25-25 11:30AM
Apr-23-25 08:00AM
Apr-16-25 08:00AM
07:15AM
Apr-02-25 08:37AM
Apr-01-25 08:00AM
Mar-25-25 09:00AM
07:30AM Loading…
Mar-24-25 07:30AM
07:16AM
Mar-14-25 11:40AM
Mar-13-25 08:00AM
Mar-04-25 08:00AM
07:45AM
Dec-27-24 02:56AM
Dec-19-24 09:00AM
08:25AM
Dec-10-24 08:30AM
08:15AM
Nov-20-24 07:44AM
Oct-29-24 10:57AM
Oct-28-24 01:41PM
07:30AM
05:34PM Loading…
Oct-27-24 05:34PM
Oct-21-24 07:30AM
Sep-27-24 07:30AM
Sep-19-24 09:00AM
Sep-18-24 07:00AM
Sep-11-24 07:30AM
Aug-26-24 08:00AM
Aug-19-24 07:30AM
Aug-12-24 08:30AM
08:00AM
Aug-05-24 09:40AM
Jul-25-24 03:24PM
07:00AM
Jul-22-24 12:56PM
10:31AM
08:00AM
Jul-15-24 07:00AM
Jun-24-24 08:30AM
Jun-10-24 08:30AM
May-29-24 08:45AM
May-21-24 08:45AM
May-20-24 08:00AM
May-13-24 09:53PM
Apr-02-24 08:00AM
Apr-01-24 02:53PM
Mar-21-24 11:04AM
Mar-08-24 08:19AM
Feb-05-24 08:30AM
Dec-04-23 08:00AM
Nov-29-23 08:00AM
Nov-21-23 10:42AM
10:09AM
Nov-20-23 08:00AM
Oct-26-23 07:23AM
Sep-18-23 08:30AM
Sep-05-23 08:31AM
Aug-31-23 08:31AM
Aug-29-23 11:39AM
Aug-09-23 09:35AM
Aug-03-23 02:40PM
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. It engages in developing its product candidates, Ketamir-2 and MIRA-55, designed to address unmet medical needs in pain management, depression, PTSD, and cognitive function. The company was founded by Adam Kaplin on September 3, 2020 and is headquartered in Miami, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Aminov ErezChief Executive OfficerNov 19 '24Sale1.3955,41077,0201,105,790Nov 27 04:15 PM
Aminov ErezChief Executive OfficerNov 20 '24Sale1.2744,59056,6291,061,200Nov 27 04:15 PM
Erez AminovAffiliateNov 19 '24Proposed Sale1.41100,000141,000Nov 19 05:58 PM
Brian McNultyaffiliateSep 04 '24Proposed Sale1.8010,00018,000Sep 04 08:20 PM
McNulty Brian Patrick10% OwnerAug 28 '24Sale1.96200,000392,0002,540,270Aug 30 04:05 PM